Skip to main content
OpenTrials
Completed

NCT Number: NCT01949857

The Immunogenicity and Safety of Inactivated and Live Attenuated Hepatitis A Vaccines

The purpose of this Phase 4 trial is to assess the safety, immunogenicity, three-year immune persistence of inactivated hepatitis A vaccine (HAV) and live attenuated HAV vaccine.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 month–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Institute of Medical Biology -Chinese Academy of Medical Sciences

Kunming, Yunnan, 650118, China

About this study

Hepatitis A refers to liver inflammation caused by infection with the hepatitis A virus. HAV is is one of the most common hepatitis viruses that can cause hepatitis in China. The data from the phase 1, 2 and 3 trials suggested that both inactivated hepatitis A vaccine and live attenuated hepatitis A vaccine had a clinically acceptable safety and good immunogenicity for healthy Chinese people.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Only subjects fulfilling all of the following criteria will be eligible for the study:
  • People aged from 18 months to 65 years old.
  • The subjects or subjects' guardians are able to understand and sign the informed consent
  • The subjects or subjects' guardians allow to comply with the requirements of the protocol
  • Subjects with temperature <=37.0°C on axillary setting
  • The subjects have signed informed consent already

Exclusion criteria

  • Subjects will not be eligible for the study if any of the following criteria is met:
  • Subject who has a medical history of serious disease including Tumor, autoimmune disease, progressive atherosclerosis diseases or complications of diabetes, chronic obstructive pulmonary disease (copd), kidney disease, congestive heart failure etc.
  • Have a history of neurological symptoms or signs
  • Have medical history or family history relating to allergies, seizures, epilepsy, brain and spirit etc.
  • Suffering from serious chronic diseases
  • Suffering from known or suspected of diseases including respiratory diseases, acute infection , mothers have HIV infection, cardiovascular disease, severe hypertension, skin diseases, malignant tumor
  • Allergic to any ingredient in research, history of allergies to any vaccination (always), especially for people allergic to high protein food like eggs and milk
  • Any prior known or suspected damage or abnormal immune function. As for patients who are treated with immune inhibitors or immune enhancer medicine, accept with immunoglobin, blood products and plasma extraction within 3 months
  • Any prior diseases including human immunodeficiency virus infection or related
  • Bleeding constitution or prolong bleeding time situation
  • Accept hepatitis A vaccination within a month
  • Received vaccines, other immune globulin, any research drug injections in the past 4 weeks
  • People who had any acute illness, needed systemic antibiotics or antiviral treatment in the past 7 days
  • Caught a fever with axillary temperature 38°C or higher in past 3 days
  • Take part in another clinical researchers
  • Any medical, psychiatric, social condition, occupational reason or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a volunteer's ability to give informed consent
  • Pregnancy test result is positive

Treatment and study plan

Attenuated HAV Vaccine, H2 Strain

Biological

6.50 lgCCID50/Vial in babies aged 18-35 months\\6.50 lgCCID50/Vial in children aged 3-15 years \\6.50 lgCCID50/Vial in adults aged 16 up to 65 years old, only one dose (1Vial/dose).

Other names: Hepatitis A (Live) Vaccine, Freeze-dried

Attenuated HAV Vaccine, L-A-1 Strain

Biological

6.50 lgCCID50/Vial in babies aged 18-35 months\\6.50 lgCCID50/Vial in children aged 3-15 years \\6.50 lgCCID50/Vial in adults aged 16 up to 65 years old, only one dose (1Vial/dose).

Other names: Hepatitis A Vaccine

Inactivated HAV Vaccine, Lu8 Strain

Biological

320EU/Vial in babies aged 18-35 months\\320EU/Vial in children aged 3-15 years \\640EU/Vial in adults aged 16 up to 65 years old\\boost at month 6\\two-dose

Other names: Hepatitis A Vaccine, Inactivated

Inactivated HAV Vaccine, TZ84 Strain

Biological

250U/Vial in babies aged 18-35 months\\250U/Vial in children aged 3-15 years \\500U/Vial in adults aged 16 up to 65 years old\\boost at month 6\\two-dose.

Other names: Hepatitis A Vaccine, Inactivated

Primary outcomes

  1. changes of hepatitis A antibody concentration

    Time frame: up to 43 months

    • Changes of anti-HAV antibody geometric mean concentrations at pre-vaccination, month 1,12, 24, 36, and 1 months after the booster vaccination.

Secondary outcomes

  1. The frequency of all the adverse events in vaccine group and placebo group

    Time frame: up to 43 months

    compare frequency of all the solicited events, unsolicited adverse events and serious adverse events between vaccine group and placebo group.

Sponsors and collaborators

Lead sponsor

Institute of Medical Biology, Chinese Academy of Medical Sciences

Other

Collaborators

  • Jiangsu Province Centers for Disease Control and Prevention

Registry information

Official study title

Phase 4 Clinical Trial to Assess the Safety, Immunogenicity,Three-year Immune Persistence of Inactivated Hepatitis A Vaccine (HAV) and Live Attenuated HAV Vaccine

Acronym: HAV

Important dates

Study start
2013
Primary completion
2015
Study completion
2016
First posted
Sep 25, 2013
Registry last updated
Oct 10, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.